Vous êtes ici

Home › Inscriptions › Sciences Biologiques › Biocure Technology Inc.

Biocure Technology Inc.

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
CURE.X
Indice CSE: 
Devise: 

Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.

Vous êtes ici

Accueil

Biocure Technology Inc. (CURE.X)

SEDAR Information

Formulaire de recherche

Information d'entreprise

Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
Canada
Téléphone
604-609-7146
Fax
N/A
Courriel
[email protected]
URL
http://www.biocuretech.com
Date d’inscription à la cote
Lundi, mai 10, 2010
Relations avec les investisseurs
n/a
Vérificateur
DMCL Chartered Professional Accountants

Capitalisation

Capitalisation: 
94000537
Réservé à l'émission: 
14510547

Company Officers

Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer

Communiqués de presse

27/11/2023

Biocure Closes Shares for Debt Transaction

19/11/2023

Biocure Announces Shares for Debt Transaction

Bulletins

04/07/2024

2024-0701 - Reprise et Changement de Symbole - Désignation Inactive - Biocure Technology Inc. (CURE)

le 4 juillet/July 2024

Dépôts CSE

Form 9 - Notice of Issuance of Securities - Shares for Debt - Closed

Form 6 - Certificate of Compliance

Form 9 - Proposed Issuance of Securities - Shares for Debt

Form 13 - Amendment of Warrant Terms

Receipt of Proceeds